Henry Rozycki, MD

Professor

Division

Research areas

Dr. Rozycki's major focus over the years has focused on the question of why the lungs of a premature infant are more susceptible to damage and impaired development. Beginning with the role of inflammation, particularly cytokines, he has compared preterm and term alveolar macrophages, dendritic cells, and more recently, type I epithelial cells. This has led to new studies on the interaction between the type I cell and the developing extracellular matrix.

In the clinical arena, a fellow's project to design a newborn assessment that improves upon the traditional Apgar score has led to further studies on assessing the baby at delivery, and how video recordings can be used to create a better scoring system.

He was asked to substitute for someone at a meeting with a local school system regarding placement of a health clinic in a local school and this has led, over the last three years to a new interest in the provision of and effects of telehealth-based care in high-need elementary schools.

See full bibliography

Active grants

Role of Type I Lung Epithelial Cells in Development of Alveolar Simplification in BPD - Little Giraffe Foundation.
C3671008: A Phase 3, Randomized, Double-or Observer-blinded, Placebo-controlled Trial to Evaluate the Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy - Pfizer
SHP607-202: A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age - Shire/Takeda"

Collaborators

Internal (VCU):

Miheret Yitayew, MD, MPH
Russell Moores, Jr., MD
Joseph Khoury, MD
Rebecca Heise, PhD
Romesh Wijesooriya, MD

External:

Elizabeth Foglia, MD (UPenn)
Mario Rudiger, MD, PhD (Dresden)

CHRI theme

Emergency/Cardiovascular/Intensive/Pulmonary (EPIC), Health Equity, Personalized and Translational Medicine

< BACK